加载中
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
收盘时
US$4.30
−US$0.24 · -5.29%
盘后
US$4.28
−US$0.02 · -0.47%
10月13日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
日内区间
当前US$4.30
52周区间
当前US$4.30
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
47
合理估值
情绪
70
看涨
风险
49
风险偏高
动量
39
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
日内区间
当前US$4.30
52周区间
当前US$4.30
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.16亿 USD | 1.99亿 USD | 1.93亿 USD | 2.54亿 USD | 2.69亿 USD |
| 销货成本 | 1304.4万 USD | 1131.4万 USD | 1479.6万 USD | 2428.2万 USD | 2562.9万 USD |
| 毛利 | 2.03亿 USD | 1.87亿 USD | 1.78亿 USD | 2.3亿 USD | 2.43亿 USD |
| 研究与开发 | 1.09亿 USD | 7443.1万 USD | 7682.3万 USD | 8577万 USD | 7536.3万 USD |
| 销售、一般及管理费用 | 2.38亿 USD | 1.46亿 USD | 1.13亿 USD | 1.36亿 USD | 1.24亿 USD |
| 营业费用 | 3.54亿 USD | 2.28亿 USD | 1.92亿 USD | 2.24亿 USD | 2.01亿 USD |
| 利息收入 | — | — | — | — | 19.9万 USD |
| 折旧和摊销 | 1191.7万 USD | 813.2万 USD | 301万 USD | 273.3万 USD | 284.1万 USD |
| 营业利润 | −1.51亿 USD | −4066万 USD | −1395.2万 USD | 632.9万 USD | 4216.5万 USD |
| 净利润 | −2.2亿 USD | −1890万 USD | 250.9万 USD | 627.5万 USD | 3315.2万 USD |
公司数据更新于 2026年10月14日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$15.50
上涨空间 260.47%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI951.39万0.00%2.3万亿 USD0.03%US$381.32-0.07%
State Street SPDR S&P Biotech ETFXBI846.97万0.08%103.03亿 USD0.35%US$146.8-3.04%
iShares Russell 2000 ETFIWM634.33万0.01%777.48亿 USD0.19%US$276.7-0.43%
Vanguard Extended Market ETFVXF386.17万0.00%954亿 USD0.05%US$232.54-0.42%
iShares Russell 2000 Value ETFIWN232.88万0.02%137.52亿 USD0.24%US$210.99-0.05%
Dimensional - US Small Cap ETFDFAS207.41万0.01%338.04亿 USD0.31%US$78.33+0.20%
iShares Biotechnology ETFIBB201.66万0.02%107.38亿 USD0.44%US$200.02-2.08%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV180.38万0.01%268.33亿 USD0.33%US$38.17+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBU.S. Small Cap Value Portfolio ETF Class SharesDFSVAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
